LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Cortés, Javier; Cescon, DW; Rugo, Hope S.; Im, Sungbin; Yusof, Mastura Md; Gallardo, Carlos; Lipatov, Oleg; Barrios, Carlos H.; Perez-Garcia, J. M.; Iwata, Hiroji; Masuda, Norikazu; Otero, Marco Torregroza; Gökmen, Erhan; Loi, S.; Guo, Zifang; Zhou, Xuan; Karantza, Vassiliki; Pan, Wei‐Jian; Schmid, Peter

doi:10.1016/j.annonc.2021.08.2089

Cited by 44 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, more patients in IMpassion131 had received prior taxanes than those in IMpassion130, whereas more patients in IMpassion130 had de novo metastatic disease than those in IMpassion131 ( 18 , 61 ). Although exposure to steroids had been considered a potential confounding factor, the use of steroids in the KEYNOTE-355 trial described below makes this unlikely ( 17 , 19 ).…”

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

“…The success of this phase III trial resulted in the full regulatory approval of pembrolizumab in combination with chemotherapy in patients with PD-L1-positive TNBC, defined as a combined positive score (CPS) ≥10, and representing about 38% of patients with metastatic TNBC ( 74 ). Treatment with pembrolizumab compared to placebo resulted in a statistically significant improvement in PFS (9.7 vs 5.6 months, HR 0.65, p=0.0012 and OS (23 vs 16.1 months, HR 0.73, p=0.0093), as well as improving objective response rate (ORR, 53.2% vs 39.8%) and duration of response (19.3 vs 7.3 months) in patients whose tumors expressed PD-L1 (CPS ≥10) ( 17 , 19 ).…”

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Magbanua

Gümüşay

Kurzrock³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Liquid biopsy biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are noninvasive diagnostics that could complement predictive and prognostic tools currently used in the clinic. Recent trials of immunotherapy have shown promise in improving outcomes in a subset of breast cancer patients. Biomarkers could improve the efficacy of immune checkpoint inhibitors by identifying patients whose cancers are more likely to respond to immunotherapy. In this review, we discuss the current applications of liquid biopsy and emerging technologies for evaluation of immunotherapy response and outcomes in breast cancer. We also provide an overview of the status of immunotherapy in breast cancer.

show abstract

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Magbanua

Gümüşay

Kurzrock³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In TNBC, however, chemotherapy combination of Atezolizumab enhanced the antitumor efficacy of Nab-paclitaxel only in patients with PD-L1 expression on tumor-infiltrating immune cells [NCT03371017] ( 26 ). On the other hand, chemotherapy combination of pembrolizumab paclitaxel protein-bound, or paclitaxel, or gemcitabine plus carboplatin also benefit patients with TNBC [NCT02819518] ( 70 ). Above all, tumors that respond to immune checkpoint inhibitors are typically so-called thermal or “hot” tumors with CD8 T cell infiltration, indicating that tumor cells are recognized by the immune system.…”

Section: Combination Therapymentioning

confidence: 99%

Prospects of Immunotherapy for Triple-Negative Breast Cancer

et al. 2022

View full text Add to dashboard Cite

In the classification and typing of breast cancer, triple-negative breast cancer (TNBC) is one type of refractory breast cancer, while chemotherapy stays in the traditional treatment methods. However, the impact of chemotherapy is short-lived and may lead to recurrence due to incomplete killing of tumor cells. The occurrence, development, and relapse of breast cancer are relevant to T cell dysfunction, multiplied expression of related immune checkpoint molecules (ICIs) such as programmed death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) produce immunosuppressive effect. Immunotherapy (namely, immune checkpoint inhibitors, adoptive cellular immunotherapy, CAR-T immunotherapy and some potential treatments) provides new hope in TNBC. This review focuses on the new immune strategies of TNBC patients.

show abstract

“…The phase III IMpassion132 study of gemcitabine plus carboplatin/capecitabine with or without atezolizumab as the first-line therapy of TNBC is ongoing (NCT03371017). In the phase III KEYNOTE-355 study (26,27), pembrolizumab combined with chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine/carboplatin) as the first-line treatment of advanced TNBC mainly benefited patients with ≥10% PD-L1 expression (detected by PD-L1 22C3 pharmDx assay) disease, with a median PFS of 9.7 months in combination group versus 5.6 months in chemotherapy group (HR 0.66, 95% CI 0.50-0.88).With respect to grades 3-5 AEs, 68.1% patients experienced that in the combination group (2 deaths), in contrast with 66.9% in the chemotherapy group (0 death). However, more patients suffered grades 3-4 immune-related AEs and infusion reactions in the immunochemotherapy group (5.5% vs. 0%).…”

Section: Combination Of Immunotherapy and Chemotherapymentioning

confidence: 99%

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy

Chen

Gao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major killer of women’s health worldwide. While breast cancer is thought to have lower immunogenicity compared with other solid tumors, combination therapy is able to improve the immunogenicity of the tumor and sensitize breast cancer cells to immunotherapy. Immunotherapy represented by immune checkpoint inhibitors (ICIs) has been largely explored in the field of breast cancer, including both early and advanced disease. Immunotherapy for triple-negative breast cancer (TNBC) has been the most studied, and the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel has been used in the first-line treatment of TNBC. Immunotherapeutic data for human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer are also accumulating. This review summarizes the clinical trial data of ICIs or ICI-containing therapies in different types and stages of breast cancer.

show abstract

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Cited by 44 publications

References 0 publications

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Prospects of Immunotherapy for Triple-Negative Breast Cancer

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy

Contact Info

Product

Resources

About